Dinges Jürgen, Albert Daniel H, Arnold Lee D, Ashworth Kimba L, Akritopoulou-Zanze Irini, Bousquet Peter F, Bouska Jennifer J, Cunha George A, Davidsen Steven K, Diaz Gilbert J, Djuric Stevan W, Gasiecki Alan F, Gintant Gary A, Gracias Vijaya J, Harris Christopher M, Houseman Kathryn A, Hutchins Charles W, Johnson Eric F, Li Hu, Marcotte Patrick A, Martin Ruth L, Michaelides Michael R, Nyein Michelle, Sowin Thomas J, Su Zhi, Tapang Paul H, Xia Zhiren, Zhang Henry Q
Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, Illinois 60064-6217, USA.
J Med Chem. 2007 May 3;50(9):2011-29. doi: 10.1021/jm061223o. Epub 2007 Apr 11.
The synthesis of a novel series of 1,4-dihydroindeno[1,2-c]pyrazoles with acetylene-type side chains is described. Optimization of those compounds as KDR kinase inhibitors identified 8, which displayed an oral activity in an estradiol-induced murine uterine edema model (ED50 = 3 mg/kg) superior to Sutent (ED50 = 9 mg/kg) and showed potent antitumor efficacy in an MX-1 human breast carcinoma xenograft tumor growth model (tumor growth inhibition = 90% at 25 mg/kg.day po). The compound was docked into a homology model of the homo-tetrameric pore domain of the hERG potassium channel to identify strategies to improve its cardiac safety profile. Systematic interruption of key binding interactions between 8 and Phe656, Tyr652, and Ser624 yielded 90, which only showed an IC50 of 11.6 microM in the hERG patch clamp assay. The selectivity profile for 8 and 90 revealed that both compounds are multitargeted receptor tyrosine kinase inhibitors with low nanomolar potencies against the members of the VEGFR and PDGFR kinase subfamilies.
描述了一系列具有乙炔型侧链的新型1,4-二氢茚并[1,2-c]吡唑的合成。将这些化合物优化为KDR激酶抑制剂后确定了化合物8,其在雌二醇诱导的小鼠子宫水肿模型中显示出优于舒尼替尼(ED50 = 9 mg/kg)的口服活性(ED50 = 3 mg/kg),并在MX-1人乳腺癌异种移植肿瘤生长模型中显示出有效的抗肿瘤功效(25 mg/kg·天口服给药时肿瘤生长抑制率 = 90%)。将该化合物对接至hERG钾通道同四聚体孔结构域的同源模型中,以确定改善其心脏安全性的策略。对化合物8与苯丙氨酸656、酪氨酸652和丝氨酸624之间的关键结合相互作用进行系统性阻断后得到了化合物90,其在hERG膜片钳试验中仅显示出11.6 μM的IC50。化合物8和90的选择性概况表明,这两种化合物均为多靶点受体酪氨酸激酶抑制剂,对VEGFR和PDGFR激酶亚家族成员具有低纳摩尔级别的活性。